Vascular Biogenics Ltd. (VBLT)
| Market Cap | 131.07M |
| Revenue (ttm) | 843,000 |
| Net Income (ttm) | -22.70M |
| Shares Out | 47.90M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $2.63 |
| Previous Close | $2.72 |
| Change ($) | -0.09 |
| Change (%) | -3.31% |
| Day's Open | 2.81 |
| Day's Range | 2.51 - 2.81 |
| Day's Volume | 358,451 |
| 52-Week Range | 0.96 - 2.91 |
Agreement extends current cash runway to Q1 2023 Agreement extends current cash runway to Q1 2023
TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111...
TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first...
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2020 Results - Earnings Call Transcript
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 28.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...
Shares of Vascular Biogenics (NASDAQ:VBLT) moved higher by 0.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 14.29% year over year ...
- Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient popula...
TEL AVIV, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first...
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first...
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to...
TEL AVIV, Israel, Oct. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328408, which covers VBL’s propr...
TEL AVIV, Israel, Sept. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of fi...
TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of fi...
TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wain...
TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investi...
TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 i...
TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Adminis...
Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2020 Results - Earnings Call Transcript
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -15.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Vascular Biogenics (NASDAQ:VBLT) decreased 9% in pre-market trading after the company reported Q2 results.
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre...
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of fir...
The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer The company's bi-specific antibody candidates significan...
TEL AVIV, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced the presentation of the positive outcome of pre-planned interim analysis results from the...
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2020 Results - Earnings Call Transcript
Shares of Vascular Biogenics (NASDAQ:VBLT) were flat in pre-market trading after the company reported Q1 results.
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 6.25% and 89.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call and Webcast at 8:30am Eastern Time Today Conference Call and Webcast at 8:30am Eastern Time Today
Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings Raised $18.1 Million of Gross Proceeds in Two Registered Direct Offerings
TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordina...
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for th...
TEL AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its anti-MOSPD2 antibodies for t...
Data were published in a peer-review manuscript in Clinical & Experimental Immunology Data were published in a peer-review manuscript in Clinical & Experimental Immunology
TEL AVIV, Israel, April 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels ...
TEL AVIV, Israel, April 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that it has reached a milestone event under its collaborative agreement with a world-lea...
TEL AVIV, Israel, April 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that following the positive interim analysis in the OVAL study, its Japanese licensee N...
Vascular Biogenics: A Buy On Promising Cancer Therapy
TEL AVIV, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced an encouraging outcome of the planned interim analysis in the OVAL study, a double-blind ...
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2019 Results - Earnings Call Transcript
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -23.08% and -31.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for t...
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in VBL.
Vascular Biogenics Ltd. VBLT) CEO Dror Harats on Q3 2019 Results - Earnings Call Transcript
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -67.08%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th...
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TEL AVIV, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that an investigational new drug (IND) application has received clearance from the U.S. Fo...
Vascular Biogenics' (VBLT) CEO Dror Harats on Q2 2019 Results - Earnings Call Transcript
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2019 Results - Earnings Call Transcript
About VBLT
Vascular Biogenics, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain c... [Read more...]
| Industry Biotechnology | IPO Date Oct 1, 2014 |
| CEO Dror Harats | Employees 38 |
| Stock Exchange NASDAQ | Ticker Symbol VBLT |
Financial Performance
In 2019, VBLT's revenue was $562,000, a decrease of -3.93% compared to the previous year's $585,000. Losses were -$19.46 million, -4.89% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for VBLT stock is "Buy." The 12-month stock price forecast is 4.35, which is an increase of 65.40% from the latest price.